MPM
MRNA icon

Meritage Portfolio Management’s Moderna MRNA Stock Holding History

Meritage Portfolio Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,967
Closed -$203K – 346
2023
Q3 		$203K Buy
1,967
+25
+1% +$2.79K 0.02% 319
2023
Q2 		$236K Buy
1,942
+630
+48% +$84K 0.02% 317
2023
Q1 		$201K Sell
1,312
-32
-2% -$5.28K 0.02% 301
2022
Q4 		$241K Buy
+1,344
New +$220K 0.02% 285
2022
Q3 		– Sell
-1,576
Closed -$225K – 322
2022
Q2 		$225K Hold
1,576
– – 0.02% 279
2022
Q1 		$271K Sell
1,576
-35,670
-96% -$6.01M 0.02% 286
2021
Q4 		$9.46M Buy
37,246
+36,123
+3,217% +$10.6M 0.54% 47
2021
Q3 		$432K Sell
1,123
-23
-2% -$8.48K 0.03% 218
2021
Q2 		$269K Sell
1,146
-443
-28% -$79.2K 0.02% 262
2021
Q1 		$208K Sell
1,589
-3,365
-68% -$488K 0.01% 273
2020
Q4 		$518K Buy
+4,954
New +$501K 0.04% 205

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Meritage Portfolio Management's MRNA Position: Q4 2023 in Review

Meritage Portfolio Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 1,967 shares — an estimated $203K sold.

Meritage Portfolio Management first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $9.46M in Q4 2021. 885 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Meritage Portfolio Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Meritage Portfolio Management sold 1,967 Moderna shares in Q4 2023, an estimated $203K.
  • Meritage Portfolio Management first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Meritage Portfolio Management's Moderna position peaked at $9.46M in Q4 2021.
  • 885 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Meritage Portfolio Management's 13F filing for Q4 2023, filed 2 Feb 2024.